Trial
NCT01037907
A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Boston Scientific Corporation
Collaborators
—
Condition
Relapsing Remitting Multiple Sclerosis
Intervention
Pleneva TM BGC20-0134
Why stopped
Lack of efficacy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-06-03